5 Gene Editing Stocks With the Best Long-Term Potential

3. Exact Sciences Corporation (NASDAQ:EXAS)

Number of Hedge Fund Holders: 39

Molecular diagnostics company Exact Sciences Corporation (NASDAQ:EXAS), which is focused on cancer, last year bought diagnostics company PreventionGenetics for $190 million. Exact Sciences Corporation (NASDAQ:EXAS) through the deal expanded its footprint in the hereditary cancer screening market.

Hedge fund sentiment for Exact Sciences Corporation (NASDAQ:EXAS) jumped in the fourth quarter of 2022. 39 hedge funds tracked by Insider Monkey had stakes in Exact Sciences Corporation (NASDAQ:EXAS), up from 34 hedge funds in the previous quarter. The most notable hedge fund stakeholder of Exact Sciences Corporation (NASDAQ:EXAS) was Catherine D. Wood’s ARK Investment Management which owns a $794 million stake.